F I G U R E 1 Diagnostic algorithm for hyponatremia from the European guideline
| ZHOU and YanG neurologic deficits observed. Further neurologic assessment by several specialists did not reveal any pathological signs.
| Diagnostic assessment
Initial laboratory tests showed the following: WBC 10.2 k/ µL, RBC 4.95 k/µL, hemoglobin 15.1 g/dL, hematocrit 47%, sodium 101 mmol/L, chloride 73 mmol/L, potassium 5.2 mmol/L, CO2 16 mmol/L, AG 11, BUN 20 mg/dL, Cr 0.8 mg/dL, and eGFR > 60 mL/min/1.73 m 2 . The rest of the biochemical analysis including liver function, calcium, phosphorus, glucose, total protein albumin, lipid panel, and globulin were within normal range. With patient's extremely low serum sodium, our attention focused on the investigation of the cause. Further tests showed plasma osmolality 225 mOsm/kg (275-295 mOsm/ kg), sodium in urine sample was 128 mmol/L, and urine osmolality 128 mOsm/kg. Since hyperglycemia and other causes of nonhypotonic hyponatremia were excluded, our patient had hypotonic hypovolemic hyponatremia. Given increased urine osmolality, elevated urine sodium, and no history of diuretic use, according to the diagnostic algorithm for hyponatremia based on the European guideline (Figure 1 ), 2 the most likely explanation was adrenal insufficiency (AI). Therefore, lab tests to evaluate adrenal function were ordered. The results showed basal morning cortisol was 6.2 µg/ dL (7-28 µg/dL) and ACTH 125 pg/mL (9-52 pg/mL), which suggests primary adrenal insufficiency. The patient failed her cortisol stimulation test afterward which confirmed the diagnosis. Thyroid function test showed TSH 12.1 mU/L (0.5-5.0 mU/L)and free T4 0.7 ng/dL (0.9-2.4 ng/dL) which revealed inadequately controlled hypothyroidism.
Review of the history: The patient had fatigue, poor appetite, unintentional weight loss, and tanned skin for at least 1 month. Five days before admission, which was 3 days after taking TMP-SMX, the patient started to have nausea and worsening fatigue. Based on the whole history and test results, our impression was that she had baseline mild-tomoderate chronic hyponatremia due to uncontrolled primary adrenal insufficiency, and this situation was acutely exacerbated by TMP-SMX use several days prior. Obviously, the cause of the patient's hyponatremia was multifactorial. We also believe that inadequately controlled hypothyroidism due to self-switching from levothyroxine to animal thyroid extract a few months prior may have played a minor role in the development of the hyponatremia.
| Treatment
After the initial diagnosis of severe hyponatremia, the TMP-SMX was discontinued immediately. The patient was given normal saline 60 mL/h, combined with fluid restriction limiting water intake to 1.5 L per day. The patient was given neither hypertonic saline nor tolvaptan because she had chronic hyponatremia and was neurologically asymptomatic. According to the guidelines, the patient has risk factor for osmotic demyelination syndrome (ODS) (Serum Na < 105 mmol/L), optimal correction rate should be <8 mmol/L per day. The patient's serum sodium level increased from 101 to 112 mmol/L in the first 22 hours, so we drove the correction rates down by holding the normal saline infusion. The patient's sodium level increased 5-8 mmol/L per day in the following days which was at our goal. The patient was monitored closely in the process of hyponatremia correction. No neurologic symptoms or signs of ODS were observed. Her serum sodium had increased gradually to 129 mmol/L with significant clinical improvement in the following days ( Figure 2 ).
Based on the final diagnosis of primary AI, the patient was treated with prednisone 5 mg daily and fludrocortisone 0.1 mg daily. At the same time, she was started on levothyroxine instead of thyroid extract to better control her hypothyroidism. The patient was discharged home with outpatient follow-up. Sodium level was 129 mmol/L at discharge.
| DISCUSSION
Hyponatremia is one of the most common electrolyte disorders in clinical practice. It is defined as a serum sodium concentration < 135 mmol/L and is considered severe when the serum level < 125 mmol/L. Symptoms of hyponatremia are primarily neurologic, ranging from nausea, vomiting, headache and malaise, to altered mental status, seizures, even coma, brain-stem herniation, and respiratory arrest, which can lead to permanent brain damage or death. In our patient, her sodium level was 101 mmol/L on admission, but F I G U R E 2 Serum sodium level during hospitalization surprisingly, the patient was neurologically asymptomatic. Such a low level of serum sodium without any CNS symptoms has not been reported before.
The severity of hyponatremia depends on the rate and extent of changes in sodium concentration. In chronic hyponatremia, neurologic symptoms are much less severe due to cerebral adaption which begins within a day of sustained hyponatremia and generally takes several days for full measures to be in place. The adaptive mechanism involves (a) a compensatory displacement of fluid from the interstitial space into the cerebrospinal fluid and from there into the systemic circulation and (b) the extrusion of intracellular solutes together with osmotically obligated water to reduce cellular swelling and normalize brain volume. The process of brain volume regulation is complex and essential to understand the variability of the clinical presentation of hyponatremia.
Severe hyponatremia is associated with high morbidity and mortality. In order to implement correct treatment, an accurate clinical assessment must be made, focusing on fluid status, chronicity, and potential etiology. As in our patient, a majority of hyponatremia patients had a complex and multifactorial etiology. It is crucial that a thorough investigation is made to secure the correct diagnosis.
| Hyponatremia and adrenal insufficiency
Hyponatremia is one of the major electrolyte abnormalities of primary adrenal insufficiency. It is mediated by increased release of antidiuretic hormone (ADH) which results in water retention and a reduction in the plasma sodium concentration. 3, 4 The possible mechanisms may include the following: Cortisol directly suppressing ADH secretion, the removal of the inhibitory effect causes ADH hypersecretion, 5-9 cortisol deficiency results in increased hypothalamic secretion of corticotropin-releasing hormone (CRH), which is an ADH secretagogue 5, 10, 11 and renal salt elimination with resultant volume depletion and blood pressure reduction in AI cause hypersecretion of ADH. Several studies have revealed hypocortisolism may increase renal sensitivity to ADH, evidenced by upregulation of aquaporin-2 water channel in glucocorticoid-deficient rats.
12,13
Primary adrenal insufficiency may well be recognized by clear hallmarks of the disease, such as hyponatremia, hyperkalemia, hypotension, hyperpigmentation, and salt craving. It is an important diagnosis not to be missed since the consequences could be fatal.
| Trimethoprim-sulfamethoxazoleinduced hyponatremia
TMP-SMX is a commonly prescribed antibiotic for various infections. TMP is structurally related to the potassium-sparing diuretic amiloride and has been associated with hyperkalemia and hyponatremia through blocking epithelial sodium channels in the collection duct.
Electrolyte disorders are the most common adverse events in HIV-infected patients treated with high doses of TMP-SMX, while hyperkalemia is much more common than hyponatremia, occurring in as many as 44%-70% of HIV patients treated with high-dose TMP-SMX. [14] [15] [16] However, a recent single-center retrospective study showed a high incidence (72.3%) of hyponatremia associated with the use of highdose TMP-SMX (8 mg/kg/d of TMP for ≥3 days) among hospitalized patients, and hyponatremia was noted on average 5.5 days after initiation of therapy. 17 Besides, a few reports have shown that even standard dose TMP-SMX can cause hyponatremia in non-HIV infected patients as well. [18] [19] [20] [21] A retrospective study confirmed that TMP-SMX is implicated not only in hyperkalemia but also in hyponatremia. These electrolyte disorders were found in 14 of 53 patients (26.4%), the average dose of TMP was 145.7 ± 24.9 mg/d, which was not high. When the patients were monitored carefully, electrolyte disorders were seen even in the low-dose group. The incidence of electrolyte disorders is increased with the dose of TMP, indicating a dose-dependent manner. 18 In our case report, since the patient took standard dose TMP-SMX for sinusitis prior to onset of symptoms, we believe TMP-SMX is the acute aggravating factor which contributes to the ultimate profound hyponatremia. TMP blocks sodium reabsorption at epithelial sodium channel in the distal nephron, leading to hyperkalemia, and inevitably, hyponatremia as a result. There are also animal studies showed TMP infusion decreases renal potassium excretion by 40% and increases renal sodium excretion by 46%, likely in a dosedependent manner. 22 Although standard dose TMP-SMX-induced hyponatremia is rare, it is still worth close attention in clinical practice. The association between hyponatremia and TMP-SMX emphasizes the need to evaluate electrolytes in patients who develop illness shortly after taking this medication, especially when patient has other risk factors or predisposing conditions of hyponatremia at the same time.
| Hyponatremia and hypothyroidism
Hyponatremia has been reported in patients with moderate-to-severe hypothyroidism, particularly in patients with myxedema. This is due in part to a reduced cardiac output, which can lead to the release of ADH via the carotid sinus baroreceptors. 23, 24 On the other hand, the glomerular filtration rate has been reported to be decreased in hypothyroidism, which leads to diminished free water excretion and dilutional hyponatremia. 25, 26 Warner et al 27 described a statistically significant association between hyponatremia and hypothyroidism: for every 10 mIu/L rise in thyroid-stimulating hormone, serum sodium decreased 0.14 mmol/L. Our patient has moderate hypothyroidism with elevated TSH of 12.1 mIU/L, which is considered a small portion if any which may contribute to the development of hyponatremia.
| Optimal correction rates of hyponatremia
Overly rapid correction of severe, chronic hyponatremia (serum sodium concentration <120 mmol/L and particularly <115 mmol/L) can lead to a severe and sometimes irreversible neurologic disorder, osmotic demyelination syndrome (ODS). 28, 29 According to United States and European hyponatremia guidelines, 2 the limit of correction rates in hyponatremia should be around 10 mmol/L per day for both acute and chronic hyponatremia. 2 Of note, the United States guideline recommends a lower limit of 8 mmol/L per day in patients with high risk of ODS (sodium ≤ 105 mmol/L, concurrent hypokalemia, alcoholism, malnutrition, or hepatic disease). Many physicians advocate a more conservative rate of correction of 6 mmol/L per day, 28, 30 although this is likely to be both sufficient and safe, the data to support this are still limited. During treatment, close monitoring of serum sodium is essential and prompt action should be taken to avoid overly rapid correction.
| Treatment of hypothyroidism
Switching to animal thyroid extract by the patient is considered the contributor to the inadequate treatment of hypothyroidism. Regarding the treatment of hypothyroidism, 31 the guidelines for the treatment of hypothyroidism by American Thyroid Association recommend levothyroxine as routine care for patients with primary hypothyroidism, in preference to the use of thyroid extracts. It is because of potential safety concerns related to the use of thyroid extracts, such as the presence of supraphysiologic serum triiodothyronine levels and a paucity of long-term safety outcome data.
| CONCLUSION
Although hyponatremia is common in clinical practice, our case report highlights that: (1) Profound hyponatremia with sodium level 101 mmol/L could have no CNS symptoms due to the remarkable adaption of brain; (2) severe hyponatremia is often multifactorial: (a) Even standard dose TMP-SMX is associated with hyponatremia which emphasized the need for greater awareness of this serious and potentially fatal complication. (b) Endocrine disorders including adrenal and thyroid dysfunction should be considered in the differential diagnosis of hyponatremia and part of hyponatremic workup. (c) Thorough evaluation is required to uncover all the predisposing conditions, and each of them must be addressed to correct hyponatremia.
